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Microglia are the primary immune cells in the CNS, aris-
ing from c-kit+ erythromyeloid precursors in the yolk sac, 
and then migrating to the developing neural tube to mature 
(Alliot et al., 1999; Ginhoux et al., 2010; Schulz et al., 2012; 
Kierdorf et al., 2013). In the brain, microglia interact with 
neurons and exert a wide variety of physiological functions 
(Chen et al., 2010; Paolicelli et al., 2011; Rogers et al., 2011; 
Derecki et al., 2012; Schafer et al., 2012; Parkhurst et al., 
2013; Zhan et al., 2014). As an integral part of the innate 
immune system, microglia constantly patrol the brain pa-
renchyma and subsequently clear pathogens, apoptotic cells, 
and cellular debris by phagocytosis under physiological and 
pathological conditions (Davalos et al., 2005; Nimmerjahn 
et al., 2005; Mildner et al., 2011). However, microglia can be 
activated by various triggering factors, such as injury, infec-
tion, or neurodegeneration, leading to morphological and 
molecular changes and release of cytokines (Aguzzi et al., 
2013a). Depending on the type of molecular stimuli and 
cues received from the surrounding microenvironment, mi-
croglia can take on many different activation profiles and 
are thought to exert both beneficial and detrimental effects 
(Hanisch and Kettenmann, 2007).
Prion diseases are progressive neurodegenerative dis-
orders associated with striking microglial activation (Aguzzi 
et al., 2013b). In animal models of prion disease, microglial 
activation and cytokine release occur at an early stage of the 
disease and are found in areas of proteinase K (PK)–resis-
tant prion protein (PrPSc) deposition, but precede spongiosis 
and neuronal loss (Williams et al., 1997; Giese et al., 1998). 
As in other protein misfolding diseases, microglia are found 
surrounding PrPSc plaques and intracellular PrPSc can be de-
tected in microglia (Jeffrey et al., 1994; Baker et al., 2002). The 
presence of high prion infectivity in microglia suggests that 
microglia may disseminate prions within the CNS (Baker et 
al., 2002). In addition, the cytokines produced by activated 
microglia may contribute to progression of the disease.
In contrast, microglia are also professional phago-
cytes in the brain and can engulf and degrade PrPSc. In-
deed, microglial depletion from CD11b-thymidine kinase 
of Herpes simplex virus (HSV TK) cerebellar organotypic 
cultured slices (COCS) infected with RML6 prions (Rocky 
Mountain Laboratories, scrapie strain passage #6) results 
in increased deposition of PrPSc and augmented prion ti-
ters, indicating that microglia play an important role in the 
clearance of prions (Falsig and Aguzzi, 2008; Falsig et al., 
2008). Nevertheless, because of the dearth of appropriate 
animal models, the exact role of microglia in prion patho-
genesis remains unknown.
In this study, we first assessed the role of microglia in 
prion pathogenesis using pharmacogenetic microglia deple-
tion ex vivo and in vivo (Heppner et al., 2005). We found that 
microglia ablation drastically enhanced the neurotoxicity of 
prions ex vivo and shortened the lifespan of prion-infected 
mice. We also administered prions to IL-34–ablated (IL34−/−) 
mice, which have a reduced number of microglia (Greter et 
al., 2012; Wang et al., 2012). We found enhanced PrPSc depo-
sition and accelerated prion progression compared with WT 
littermates. These results indicate that microglia play an over-
all protective rather than deleterious role in prion disease.
Microglial activation is a hallmark of most neurodegenerative disorders, and is particularly conspicuous in prion diseases. 
However, the role of microglia, which function as both primary immune effector cells and professional phagocytes in the cen-
tral nervous system, remains contentious in the context of neurodegeneration. Here, we evaluated the effect of microglial 
depletion/deficiency on prion pathogenesis. We found that ganciclovir-mediated microglial ablation on tga20/CD11b-thymi-
dine kinase of Herpes simplex virus (HSV TK) cerebellar organotypic cultured slices markedly aggravated prion-induced neuro-
toxicity. A similar deterioration of disease was recapitulated in in vivo microglial depletion in prion-infected tga20/CD11b-HSV TK 
mice. Additionally, deficiency of microglia in interleukin 34 knockout (IL34−/−) mice again resulted in significantly augmented 
proteinase K–resistant prion protein deposition and accelerated prion disease progression. These results provide unambiguous 
evidence for a general protective role of microglia in prion pathogenesis.
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RES ULTS
Microglial ablation increases the neurotoxicity of prions in 
the ex vivo CD11b-HSV TK system
Prion pathogenesis is faithfully reproduced in the COCS 
system (Falsig et al., 2012; Herrmann et al., 2015). Hence, we 
evaluated the role of microglia in COCS prepared from tga20 
:CD11b -HSV TK mice (tga20TK+), which were obtained by 
intercrossing mice overexpressing the cellular prion protein 
PrPC (Fischer et al., 1996) and mice expressing the HSV 
TK under the control of the CD11b promoter (Heppner et 
al., 2005). Administration of ganciclovir (GCV) to tga20TK+ 
COCS leads to complete microglial ablation after 14 d of 
treatment (Falsig et al., 2008). Therefore, tga20TK+ COCS 
were exposed to RML6 or noninfectious brain homogenate 
(NBH), and GCV-mediated microglial ablation was 
performed. At 49 d postinoculation (dpi), RML6-infected 
non–GCV-treated tga20TK+ COCS showed a significant 
decrease in the density of NeuN+ cerebellar granule 
neurons (CGN) compared with NBH-treated tga20TK+ 
COCS (Fig.  1, A and B). However, depletion of microglia 
(RML6-infected, GCV-treated tga20TK+ COCS) resulted 
in a dramatic increase in neurotoxicity, leading to subtotal 
CGN depletion in COCS (Fig. 1, A and B). Therefore, GCV 
treatment significantly increased neurotoxicity in RML6-
infected tga20TK+ cultures compared with RML6-infected, 
non–GCV-treated tga20TK+ COCS.
Figure 1. Microglia ablation on CD11b-
HSV TK COCS enhanced prion-induced neu-
rotoxicity. (A and B) Tga20TK+ or tga20TK− slices 
were treated with NBH or RML6 and cultured 
in the optional presence of GCV for 49 dpi. 
Representative COCS stained for NeuN (green) 
and DAPI (blue; A) and analyzed by NeuN mor-
phometry (B). Bars, 200 µm. n = 10–11. ***, P 
< 0.001; n.s, P > 0.05. Bars labeled Co denote 
co-culture of slices divided by a grease barrier. 
Red bars indicate microglia depletion. (C) NeuN 
morphometry of RML6 infected tga20TK+ COCS 
optionally treated with GCV and reconstituted 
with PLCs prepared from tga20 mice (∼70,000 
cells per COCS). Red: microglia-depleted, Blue: 
microglia-depleted and PLC reconstituted. n 
= 10; ***, P < 0.001; n.s, P > 0.05. (D) NeuN 
morphometry of RML6 infected tga20TK+ COCS 
optionally treated with GCV and reconstituted 
with 70 × 103 CD19−CD11b+ cells per slice. Red: 
microglia-depleted, Blue: microglia-depleted 
and CD19−CD11b+ cells reconstituted. n = 10. 
***, P < 0.001. (E) PrPSc Western blot of cultures 
prepared from Prnp−/−, tga20TK+, or tga20TK− 
mice exposed to NBH, RML6, or 22L and cul-
tured until 35 dpi in the optional presence of 
GCV. Samples were digested with PK as indi-
cated and detected with POM1. (F–I) qRT-PCR 
of cytokines and chemokines in tga20TK+ slices 
treated with NBH or RML6 at 42 dpi ± GCV. 
(J–M) qRT-PCR of cytokines and chemokines in 
tga20TK− slices treated with NBH or RML6 at 42 
dpi ± GCV. (F and J) TNF mRNA, (G and K) IL-1β 
mRNA, (H and L) RAN TES mRNA, and (I and M) 
MCP-1 mRNA. n = 3–5. *, P < 0.05; **, P < 0.01; 
***, P < 0.001; n.s, P > 0.05. Relative expression 
normalized to GAP DH expression and repre-
sented as fold change compared with nonin-
fected, non-GCV samples ± SEM. Statistical 
significance in B–D and F–M was determined 
using one-way ANO VA with Tukey’s post-test 
for multicolumn comparison. Histology, West-
ern blot, and qRT-PCR results represent at least 
three independent experiments.
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The exacerbation of neurotoxicity may be a result of 
GCV-mediated microglial ablation or of direct toxicity of 
GCV to COCS. To discriminate between these possibilities, 
NBH-exposed tga20TK+ COCS were treated with GCV. 
The viability of NeuN+ CGN was similar to that of NBH- 
exposed non–GCV-treated tga20TK+ COCS (Fig.  1  B). 
Additionally, GCV treatment of RML6-infected tga20 
(tga20TK–) COCS had no effect on neurotoxicity (Fig. 1 B). 
These results indicate that microglia are not essential for the 
long-term survival of COCS, but play a protective role in 
prion pathogenesis in COCS.
We then asked if phosphorylated GCV released from 
dying microglia might affect the viability of bystander neu-
rons in the context of prion infection. We co-cultured prion- 
infected tga20TK+ and tga20TK− slices in the presence of GCV. 
Cultures were separated by a grease barrier to prevent mi-
croglia migration from TK– to TK+ cultures but allowing for 
the exchange of solutes, including GCV and its metabolites. 
GCV-treated tga20TK− slices co-cultured with tga20TK+ slices 
developed pathology similarly to GCV-treated tga20TK− slices 
cultured separately (Fig. 1 B). Hence, we failed to detect any 
evidence that dying microglia in tga20TK+ slices release sol-
uble neurotoxic factors. Similarly, co-cultured GCV-treated 
tga20TK+ slices showed an equivalent pathology to GCV-
treated tga20TK+ slices cultured separately (Fig. 1 B), suggest-
ing that microglia in tga20TK− slices did not release soluble 
neuroprotective factors into the medium.
We previously found that microglia-depleted COCS can 
be reconstituted with peritoneal lavage cells (PLCs), and that 
this decreases PrPSc accumulation (Falsig et al., 2008). Recon-
stitution of prion-infected microglia-depleted tga20TK+ slices 
with tga20 PLCs (70,000 cells/COCS) completely repressed 
the increased toxicity in GCV-treated COCS (Fig. 1 C).
Furthermore, we used magnetic cell sorting (MACS) 
to purify CD11b+ cells from PLCs. Using this procedure, we 
achieved a 96.4% purity of the CD11b+ fraction, whereas the 
unsorted PLCs contained only 60.9% CD11b+ cells. Prion- 
infected, microglia-depleted GCV-treated tga20TK+ cultures 
were reconstituted with purified CD11b+ cells, and the de-
grees of reconstitution and cell death were assessed at 49 dpi. 
Again, reconstitution of RML6-infected tga20 COCS with 
CD11b+ PLCs restored the neuroprotection that had been 
abolished by GCV treatment (Fig.  1 D). The variability in 
NeuN values (Fig. 1, B–D) results from intrinsic variations in 
primary slice viability.
As previously reported (Falsig et al., 2008), microglial 
ablation leads to increased accumulation of PrPSc in COCS 
infected not only by RML6 but also by 22L, whereas non–
GCV-treated and GCV-treated tga20TK− COCS show similar 
accumulation of PrPSc (Fig.  1 E). In addition, prion infec-
tion up-regulated the expression of proinflammatory mark-
ers, including cytokines (TNF and IL-1β) and chemokines 
(MCP-1 and RAN TES) in COCS at late time points (42 
dpi; Falsig et al., 2012). In prion-infected tga20TK+ COCS (42 
dpi), TNF, IL1β, RAN TES, and MCP-1 were up-regulated 
(Fig. 1, F–I), but microglial depletion only abolished the ex-
pression of TNF and IL-1β in prion-infected COCS (Fig. 1, 
F and G), whereas up-regulation of RAN TES and MCP-1 
was accentuated after microglia depletion (Fig. 1, H and I). In 
tga20TK− COCS, the up-regulation of TNF, IL-1β, RAN TES 
and MCP-1 upon RML6 infection was not affected by GCV 
treatment (Fig.  1, J–M). Hence, microglia-depleted tissue 
accumulates more PrPSc but does not up-regulate TNF and 
IL-1β. Notwithstanding the significant reduction of proin-
flammatory cytokines (TNF and IL-1β), microglial ablation 
still enhanced prion pathogenesis, suggesting that microglia 
play a protective role in prion pathogenesis in COCS and 
activated microglia-derived cytokines are not important con-
tributors to prion disease (Aguzzi et al., 2013b).
Microglial ablation increases the neurotoxicity of prions in 
the in vivo CD11b-HSV TK system
Intraventricular administration of GCV to CD11b-HSV TK 
mice using osmotic minipumps efficiently depletes microglia 
in vivo (Grathwohl et al., 2009). Because microglia-depleted 
mice die after ∼4 wk of GCV administration, possibly be-
cause of intracerebral hemorrhages (Grathwohl et al., 2009), 
we intercrossed CD11b-HSV TK mice and tga20 mice to 
obtain a homozygous tga20 transgene (tga20+/+;TK+) and to 
enable microglial depletion in an accelerated prion disease 
model (Fischer et al., 1996). We inoculated tga20+/+;TK+ and 
tga20+/+;TK− mice with RML6 or NBH intracerebrally. At 
38 dpi, we implanted osmotic minipumps loaded with GCV 
(microglia depletion) or PBS (for control) that delivered the 
compounds into the ventricle. RML6-infected tga20+/+;TK− 
mice treated with PBS or GCV and tga20+/+;TK+ mice treated 
with PBS developed terminal scrapie with median incubation 
times of 56–57 dpi (Fig. 2 A). In contrast, tga20+/+;TK+ mice 
treated with GCV showed a median incubation time of 50 
dpi, with a highly significant acceleration of progression com-
pared with PBS-treated tga20+/+;TK+ mice (7 d; P < 0.0001; 
Fig. 2 A); under no other conditions were tga20 mice reported 
to develop scrapie so rapidly. Life span reduction was caused 
by neither microglia depletion alone nor by the surgical im-
plantation of osmotic pump; PBS-treated tga20+/+;TK+ mice 
inoculated with NBH survived up to 100 d postimplantation 
(138 dpi) and GCV-treated tga20+/+;TK+ mice inoculated with 
NBH died at 24 d postimplantation, whereas RML6-infected 
GCV-treated tga20+/+;TK+ mice became terminally sick at 12 
d postimplantation (Fig. 2 A).
RML6-infected tga20+/+;TK+ mice treated with GCV 
showed a marked depletion of microglia in the cortex (82% 
reduction), compared with RML6-infected PBS treated 
tga20+/+;TK+ or GCV-treated tga20+/+;TK− mice (Fig. 2, B and 
C). Noninfected tga20+/+;TK+ mice showed a slightly less ef-
ficient microglia depletion (63% reduction), suggesting that 
prion infection enhanced GCV-mediated microglia depletion 
(Fig. 2 C). Similarly, microglia depletion was observed in the 
cerebellum, showing that widespread microglia depletion was 
efficiently attained (Fig.  2  D). In agreement with previous 
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studies (Grathwohl et al., 2009), we did not observe aplastic 
anemia as a result of GCV delivery directly to the brain of 
HSV TK-expressing mice (Fig. S1).
Accelerated prion pathogenesis in 
microglia-deficient IL34−/− mice
To further validate the protective role of microglia in prion 
pathogenesis, IL34−/− mice that contain a reduced number of 
microglia (Wang et al., 2012), but express a similar amount of 
PrPC as WT mice (Fig. 3, A and B), were intracerebrally inoc-
ulated with RML6 prions. Mice were monitored for clinical 
signs of scrapie. The incubation time was defined as the time 
lag between prion inoculation and the time at which mice 
were euthanized, which corresponded to the terminal stage 
of prion disease. We found that both female and male IL34−/− 
mice showed significantly accelerated prion progression when 
compared with age- and gender-matched WT littermates 
(median survival 162 dpi for female IL34−/− vs. 176 dpi for 
female IL34+/+, P = 0.0025; median survival 170 dpi for male 
IL34−/− vs. 191 dpi for male IL34+/+, P < 0.0001; Fig. 3 C).
To address whether the accelerated prion progression 
in IL34−/− mice resulted from the deficiency of microglia 
and impaired PrPSc clearance, we compared PrPSc levels at 
a presymptomatic and at a clinically overt stage (105 dpi at 
∼5 mo of age and 150 dpi at ∼7.5 mo of age, respectively). 
Clinically sick mice showed a characteristic scrapie pheno-
type with waddling gait, mildly reduced grooming, and initial 
paresis. We observed significantly more PrPSc deposition in 
IL34−/− brains, suggesting that microglia play a protective role 
in prion pathogenesis by, at least partially, clearing PrPSc in 
the brain (Fig. 3, D–G).
Surprisingly, the density of microglia did not differ be-
tween IL34−/− and their WT littermates at 105 dpi and 150 
dpi (Fig.  4, A–D). Because IL-34−/− mice contain less mi-
Figure 2. Microglia ablation on in vivo 
CD11b-HSV TK system deteriorated prion 
disease. (A) Survival curves of RML6- or 
NBH-inoculated tga20+/+;TK+ or tga20+/+;TK− mice 
implanted with GCV or PBS containing intra-
ventricular osmotic minipumps (tga20+/+;TK− 
RML(PBS), n = 5, median survival = 56 dpi; 
tga20+/+;TK− RML(GCV), n = 4, median survival = 
56.5 dpi; tga20+/+;TK+ NBH(PBS), n = 6, remained 
asymptomatic up to 138 dpi; tga20+/+;TK+ 
NBH(GCV), n = 6, median survival = 61.5 dpi; 
tga20+/+;TK+ RML(PBS), n = 9, median survival = 
57 dpi; tga20+/+;TK+ RML(GCV), n = 10, median 
survival = 50 dpi; ****, P < 0.0001). Dashed line 
represents time of pump implantation. Microg-
lia-depleted mice showed an accelerated prion 
progression as compared with all other groups. 
(B) Iba1 immunohistochemistry of cortical brain 
tissue from all experimental groups showing 
dramatic reduction in the microglial coloniza-
tion of GCV-treated, RML6-infected tga20+/+;TK+ 
mice. Bars, 10 µm. (C and D) Quantification of 
microglia depletion in (C) cortical (tga20+/+;TK+ 
RML(PBS), n = 8; tga20+/+;TK+ RML(GCV), n = 
9; tga20+/+;TK− RML(GCV), n = 7; tga20+/+;TK+ 
NBH(GCV), n = 5; **, P < 0.01; ***, P < 0.001) 
or (D) cerebellar tissue (tga20+/+;TK+ RML(PBS), n 
= 8; tga20+/+;TK+ RML(GCV), n = 9; tga20+/+;TK− 
RML(GCV), n = 8; tga20+/+;TK+ NBH(GCV), n = 5; 
***, P < 0.001; **, P < 0.01). Red, microglia de-
pleted. Error bars represent SEM. Statistical sig-
nificance in A was determined using Log-rank 
(Mantel-Cox) test. Statistical significance in C 
and D was determined using one-way ANO VA 
with Tukey’s post-test for multicolumn com-
parison. Histology results represent at least five 
independent experiments.
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croglia under physiological conditions (Greter et al., 2012; 
Wang et al., 2012), this finding suggests that the proliferative 
stimulus exerted by prion infection can partially compensate 
for the lack of IL-34. However, in this situation, microglia 
may be less effective at clearing PrPSc (Hughes et al., 2010; 
Gómez-Nicola et al., 2013).
Cytokine profiling was also performed and no signif-
icant difference was observed between these two groups, 
indicating that IL-34 is not involved in prion-induced cyto-
kine expression (Fig. 4, E–J). On the contrary, we observed 
significantly more astrogliosis (GFAP immunoreactivity) in 
IL34−/− brains (Fig. 4, K–N), probably as a result of enhanced 
PrPSc accumulation. In terminally sick IL34−/− (∼8-mo-old) 
and WT (∼8.5-mo-old) littermates, which showed scrapie 
symptoms including ataxia, paresis, and reduced activity, no 
obvious difference in PrPSc deposition (Fig. 5, A and B), mi-
croglial activation (Fig. 5, C and D), or astrogliosis was ob-
served (Fig. 5, E–F). In summary, in the microglia deficiency 
IL34−/− mouse model we confirmed that microglia play an 
overall protective role in prion pathogenesis.
DIS CUS SION
Neuroinflammation is a term that was originally coined 
to denote lymphocytic and purulent CNS infiltrates that 
Figure 3. Microglia-deficient IL34−/− mice demon-
strated accelerated prion pathogenesis. (A) qRT-PCR 
for Prnp mRNA in one hemisphere of IL34−/− and IL34+/+ 
brains. n = 4. n.s, P > 0.05. (B) PrPC Western blot for 
one hemisphere from IL34−/− and IL34+/+ brains. n = 4. 
(C) Survival curves of RML6 infected IL34−/− and IL34+/+ 
(WT) mice. Median survival of IL34−/− females 162 dpi (n 
= 17) versus IL34+/+ (WT) females 176 dpi (n = 17). **, P 
< 0.01; median survival of IL34−/− males 170 dpi (n = 8) 
versus IL34+/+ (WT) males 191 dpi (n = 15). ****, P < 0.0001. 
(D and E) Hematoxylin and eosin and SAF84 staining on 
RML6-infected IL34−/− and IL34+/+ (WT) brains at 105 dpi 
(D) and 150 dpi (E). Bars, 50 µm. (F and G, left) PrPSc West-
ern blot of homogenates prepared from one brain hemi-
sphere of RML6-infected IL34−/− and IL34+/+ (WT) mice at 
105 dpi (F) and 150 dpi (G). Samples were digested with 
PK as indicated and detected with POM1. (right) Densito-
metric quantification of the PrPSc Western blot. n = 4 (105 
dpi) or 5 (150 dpi) for IL34−/−; n = 4 (105 dpi) or 6 (150 
dpi) for IL34+/+. **, P < 0.01; *, P < 0.05. Error bars represent 
SEM. Survival curves summarize two independent i.c inoc-
ulation experiments. Statistical significance in A, F, and G 
was determined using unpaired Student’s t test. Statistical 
significance in C and D was determined using Log-rank 
(Mantel-Cox) test. qRT-PCR, histology, and Western blot 
results represent at least four independent experiments.
 o
n
 June 1, 2016
jem.rupress.org
D
ow
nloaded from
 
Published May 16, 2016
Microglia confer neuroprotection in prion diseases | Zhu et al.1052
Figure 4. Microglia-deficient IL34−/− mice displayed similar microglial activation, but augmented astrogliosis. (A, left) Iba1 immunohistochem-
istry of brain tissues from RML6-infected IL34−/− and IL34+/+ (WT) mice at 105 dpi. (right) Quantification of the Iba1 immunostaining. n = 4; n.s, P > 0.05. 
Bars, 20 µm. (B, left) Iba1 immunohistochemistry of brain tissues from RML6-infected IL34−/− and IL34+/+ (WT) mice at 150 dpi. (right) Quantification of the 
Iba1 immunostaining. n = 3; n.s, P > 0.05. Bars, 20 µm. (C, left) Iba1 Western blot of one hemisphere from RML6-infected IL34−/− and IL34+/+ (WT) mice at 
105 dpi. (right) Densitometric quantification of the Iba1 Western blot. n = 4; n.s, P > 0.05. (D, left) Iba1 Western blot of one hemisphere from RML6-infected 
IL34−/− and IL34+/+ (WT) mice at 150 dpi. (right) Densitometric quantification of the Iba1 Western blot. n = 5; n.s, P > 0.05. (E–J) qRT-PCR of cytokines from 
one hemisphere of RML6-infected IL34−/− and IL34+/+ (WT) mice at 105 dpi (E–G) and 150 dpi (H–J). (E and H) TNF mRNA, (F and I) IL-1β mRNA, and (G and 
J) IL-6 mRNA. Relative expression normalized to GAP DH expression and represented as fold change compared with WT mice ± SEM. n = 4 (105 dpi) or 5 (150 
dpi) for IL34−/−; n = 4 (105 dpi) or 6 (150 dpi) for IL34+/+, n.s, P > 0.05. (K, left) GFAP immunohistochemistry of brain tissues from RML6-infected IL34−/− and 
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accompany infections and autoimmune diseases. More re-
cently, however, the term has been expanded to include mi-
croglial activation typically encountered in neurodegenerative 
diseases that do not have a primary inflammatory pathogen-
esis, such as Alzheimer’s disease, Parkinson’s disease, and prion 
disease (Aguzzi and Falsig, 2012). The contribution of mi-
croglial activation to the pathogenesis of these diseases has 
emerged as a central question and may encompass both ben-
eficial and detrimental aspects. Microglia are immune cells, 
which respond to various stimuli that trigger the release of 
proinflammatory factors that could potentially damage the 
brain. However, microglia are professional phagocytes that en-
gulf and degrade pathogens and apoptotic bodies, and there-
fore also exert protective and defensive functions in the CNS. 
The overall role of microglia in neurodegeneration is likely to 
depend on environmental cues, many of which remain unde-
ciphered, which can turn microglia into either friends or foes 
in disparate conditions.
Among the neurodegenerative disorders, prion diseases 
are associated with the most dramatic microglial activation. 
Although a role for microglia in prion diseases was implicated 
in a study using prion protein–derived peptide PrP106-126 
(Brown et al., 1996), that peptide has never been detected in 
vivo and is not infectious per se, which raises serious doubts 
about the validity of those findings. Another study demon-
strated that blocking microglial proliferation with a CSF1R 
inhibitor could slow neuronal damage and disease progression 
(Gómez-Nicola et al., 2013), suggesting a harmful contribu-
tion of microglia to prion disease. However, the overall role 
of microglia in prion diseases has remained unclear, largely 
because of the lack of an appropriate mouse model.
Here, we reasoned that the aforementioned question 
might be best studied by using several model systems that 
modify microglial functions in independent ways. Because 
organotypic CD11b-HSV TK COCS allow for the most 
radical—yet exquisitely specific—ablation of microglia, we 
opted to investigate prion pathogenesis in this system. We 
previously reported that microglial ablation from short-term 
COCS unleashes prion replication (Falsig et al., 2008), but at 
that time we had not yet discovered that prion infection leads 
to neurodegeneration in long-term COCS. Consequently, 
we had been unable to investigate whether microglia ablation 
would affect neurodegeneration, either positively or nega-
tively. The improved COCS culture system used here allowed 
us to address the latter question. Not only did we confirm 
our previous study that depletion of microglia in COCS leads 
to enhanced PrPSc deposition, but we also detected a dra-
matic acceleration in prion-induced neurodegeneration of 
the cerebellar granule layer. Notably, microglia ablation does 
not affect antiprion antibody-induced neurotoxicity (Sonati 
et al., 2013), suggesting that microglia exert neuroprotection 
by reducing the prion load rather than by acting on down-
stream events shared by prion infections and antiprion anti-
body treatment (Herrmann et al., 2015).
The notion that microglia protects the brain against 
prion-induced neurotoxicity was confirmed in vivo using 
CD11b-HSV TK transgenic mice. This model results in dras-
tic microglia reduction, yet it suffers from limitations in the 
observational time span. Because the CD11b transgene is ec-
topically expressed in hematopoietic stem cells, administra-
tion of GCV to CD11b-HSV TK+ transgenic mice leads to 
aplastic anemia and hemorrhagic diathesis. This issue can be 
alleviated (but not eliminated) by administering smaller doses 
of GCV intracerebrally through osmotic minipumps, thereby 
minimizing systemic exposure to the drug. These limitations 
forced us to devise a particularly rapid model of prion disease, 
i.e., the inoculation of mice carrying homozygous arrays of 
the tga20 transgene. Although this experimental design exag-
gerates certain aspects of prion pathology, the salient charac-
teristics of the disease (including spongiform encephalopathy, 
astrogliosis, and PrPSc deposition) are faithfully reproduced, 
and we found that microglial depletion has a major deleteri-
ous effect on prion-induced neurodegeneration.
We then wondered whether the conclusions drawn 
from the aforementioned studies would be verifiable in a sys-
tem in which microglia are compromised. Toward that goal, 
we used IL34−/− mice that suffer from impaired microglial 
development or maintenance and reduced microglia numbers 
(Greter et al., 2012; Wang et al., 2012). We again observed mi-
croglial deficiency resulting in accelerated prion progression 
and enhanced PrPSc deposition. All of these results suggest that 
microglia play an overall protective role in prion pathogenesis.
Interestingly, although microglia numbers were reduced 
in IL34−/− mice, upon prion infection microglia reached 
numbers similar to WT littermates. We conclude that IL-34 
is not required for prion-induced microglial activation and 
proliferation. The increased deposition of PrPSc and acceler-
ated prion disease in IL34−/− brains may therefore be caused 
by the scarcity of microglia at early stages of prion infection, 
or alternatively, to poorly understood defects in the effector 
functions of microglia.
IL-34−/− mice exhibited more astrogliosis than WT mice 
at 105 and 150 dpi, probably as a consequence of enhanced 
PrPSc deposition. Alternatively, astrogliosis may conceivably 
IL34+/+ (WT) mice at 105 dpi. (right) Quantification of the GFAP immunostaining, n = 4, *, P < 0.05. Bars, 20 µm. (L, left) GFAP immunohistochemistry of brain 
tissues from RML6-infected IL34−/− and IL34+/+ (WT) mice at 150 dpi. (right) Quantification of the GFAP immunostaining. n = 3; *, P < 0.05. Bars, 20 µm. 
(M, left) GFAP Western blot of one hemisphere from RML6-infected IL34−/− and IL34+/+ (WT) mice at 105 dpi. (right) Densitometric quantification of the GFAP 
Western blot. n = 4 for IL34−/−; n = 4 for IL34+/+, *, P < 0.05. (N, left) GFAP Western blot of one hemisphere from RML6-infected IL34−/− and IL34+/+ (WT) mice 
at 150 dpi. (right) Densitometric quantification of the GFAP Western blot. n = 5, **, P < 0.01. Error bars represent SEM. Statistical significance in A–N was 
determined using unpaired Student’s t test. Histology and Western blot results represent at least three independent experiments.
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influence PrPSc deposition directly in ways that were not in-
vestigated here. We favor the former interpretation because 
terminally sick IL-34−/− mice and WT littermates displayed 
similar levels of PrPSc and a similar extent of astrogliosis.
The reduction in microglia in the IL-34−/− system was 
less pronounced than in GCV-treated tga20/CD11b-HSV 
TK mice, and microglia numbers were not significantly dif-
ferent between prion-infected IL-34+/+ and IL-34−/− mice at 
105 and 150 dpi. This unexpected finding may be a result of 
conspicuous microglia activation (and possibly proliferation) 
after prion infection. Nevertheless, exacerbation of prion pro-
gression was found in both models, thereby providing or-
thogonal lines of evidence for the protective role of microglia.
The results reported here indicate that microglia, far 
from mediating prion pathogenesis, are valiant defenders of 
the brain against prions. What might be the mechanisms by 
which microglia fight prion infections? The aforementioned 
results in concert with several previous studies converge to 
Figure 5. Similar PrPSc deposition, microglial activation, and astrogliosis in terminally sick IL34−/− and IL34+/+ mice. (A) H&E and SAF84 immu-
nohistochemistry of the hippocampi of terminally sick RML6-infected IL34−/− and IL34+/+ (WT) mice. Bars, 50 µm. (B, top) PrPSc Western blot of hemispheric 
brain homogenates prepared from terminally sick RML6-infected IL34−/− and IL34+/+ (WT) mice. (bottom) Densitometric quantification of the PrPSc Western 
blot. n = 5. (C) Iba1 immunohistochemistry of hippocampi and cortex from terminally sick RML6-infected IL34−/− and IL34+/+ (WT) mice. Bars, 20 µm. (D, top) 
Iba1 Western blot of hemispheric brain homogenates prepared from terminally sick RML6-infected IL34−/− and IL34+/+ (WT) mice. (bottom) Densitometric 
quantification of the Iba1 Western blot. n = 5. (E) GFAP immunohistochemistry of hippocampi and cortex from terminally sick RML6-infected IL34−/− and 
IL34+/+ (WT) mice. Bars, 20 µm. (F, top) GFAP Western blot of hemispheric brain homogenates prepared from terminally sick RML6-infected IL34−/− and 
IL34+/+ (WT) mice. (bottom) Densitometric quantification of the GFAP Western blot. n = 5. Error bars represent SEM. Statistical significance in B, D, and F was 
determined using unpaired Student’s t test. Histology and Western blot results represent at least five independent experiments.
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indicate that phagocytosis of prion aggregates is one of the 
dominant lines of defense deployed by microglia. The first 
suggestion derived from the finding that organotypic slices 
devoid of microglia accumulate excessive amounts of PrPSc 
(Falsig et al., 2008). Here, we show that not only PrPSc ac-
cumulation is enhanced by microglial ablation, but also neu-
rotoxicity. Second, mice lacking Milk fat globule epidermal 
growth factor 8 (Mfge8) experience enhanced prion ac-
cumulation and accelerated disease after prion inoculation 
(Kranich et al., 2010; Aguzzi et al., 2014). Mfge8 is a bifunc-
tional secreted protein that can bind both phosphatidyl serine 
and integrins, thereby providing a bridge between apoptotic 
blebs and phagocytes. Together with the observation that 
prion infectivity is typically associated with lipids (Klein et 
al., 1998; Rouvinski et al., 2014), this finding suggests that 
microglia are capable of recognizing and engulfing PrPSc ag-
gregates that expose phosphatidyl serine. The latter may de-
rive from membrane remnants of prion-infected, dying cells.
One potential caveat of the CD11b-HSV TK micro-
glia depletion model is that it does not differentiate micro-
glia from infiltrating macrophages. However, the recruitment 
of peripheral monocytes to brain parenchyma is negligible 
in prion disease (Gómez-Nicola et al., 2014), and peripheral 
macrophages other than Langerhans cells are not affected in 
IL-34−/− mice (Greter et al., 2012; Wang et al., 2012). Further 
studies are needed to determine whether IL-34 deficiency 
affects the recruitment of macrophages from the periphery to 
the CNS after prion infection.
A tentative conclusion derived from the present studies 
and previous evidence is that prionostatic strategies should 
avoid damage to microglia. Instead, it would be interesting to 
devise pharmacological tools aimed at enhancing the phago-
cytic capacity of microglia.
MAT ERI ALS AND MET HODS
Ethical statement. All animal experiments were performed in 
strict accordance with the Rules and Regulations for the 
Protection of Animal Rights (Tierschutzgesetz and Tier-
schutzverordnung) of the Swiss Bundesamt für Lebensmittel-
sicherheit und Veterinärwesen and were preemptively 
approved by the Animal Welfare Committee of the Canton of 
Zürich (permit 200/2007, 90/2013, and 41/2012).
Animals. For in vivo depletion of microglia, we intercrossed 
tga20TK+ mice with tga20 mice to obtain tga20+/+:Prnpo/o: 
CD11b-HSV TK+ mice, henceforth referred to as tga20+/+;TK+. 
To distinguish between tga20+/− and tga20+/+ mice, we per-
formed zygosity FISH for Prnp, identifying tga20+/+ founders 
according to published protocols (McHugh et al., 2012). For 
maintaining the colony, tga20+/+;TK+ females were intercrossed 
to tga20 male mice as CD11b-HSV TK+ males are sterile 
(Heppner et al., 2005). IL34−/− mice (Wang et al., 2012) car-
rying a targeted deletion of exons 3–5 were first backcrossed 
to C57BL/6J to obtain IL34+/− offspring. IL34+/− mice were 
then intercrossed to obtain IL34−/− and IL34+/+ (WT) litter-
mates, which were used for the experiments described here. 
Mice were maintained in high hygienic grade facility and 
housed in groups of 3–5, under a 12 h light/12 h dark cycle 
(from 7 a.m. to 7 p.m.) at 21 ± 1°C, with sterilized food 
(Kliba No. 3436; Provimi Kliba) and water ad libitum.
Organotypic slices culture preparation and microglial deple-
tion. Cerebellar organotypic slices were prepared from 9–11-
d-old pups and maintained according to previously published 
protocols (Falsig and Aguzzi, 2008). GCV-mediated (val-
ganciclovir; Roche) microglia depletion experiments were 
performed on brain slices prepared from CD11b-HSV TK 
mice intercrossed with tga20 mice (tga20TK+). Cultures were 
inoculated with 100 µg brain homogenate per 10 slices from 
terminally sick prion-infected (RML6 and 22L) or NBH 
from CD1 mice, diluted in 2  ml physiological Grey’s bal-
anced salt solution (GBSS; 8 g l–1 NaCl, 0.37 g l–1 KCl, 0.12 g l–1 
Na2HPO4, 0.22 g l–1 CaCl2 2H2O, 0.09 g l–1 KH2PO4, 0.07 g 
l–1 MgSO4 7H2O, 0.210 g l–1 MgCl2 6H2O, and 0.227 g l–1 
NaHCO3) supplemented with the glutamate receptor antag-
onist kynurenic acid (1 mM; GBS SK). Slices were incubated 
with infectious brain homogenates as free-floating sections 
for 1 h at 4°C. Slices were washed twice in 6 ml GBS SK and 
5–10 slices were placed on a 6-well Millicell-CM Biopore 
PTFE membrane insert (EMD Millipore). Residual buffer 
was removed and the inserts were transferred to a cell culture 
plate and cultured in slice culture medium (50% [vol/vol] 
MEM, 25% [vol/vol] basal medium Eagle, and 25% [vol/vol] 
horse serum supplemented with 0.65% [wt/vol] glucose, 
penicillin/streptomycin, and glutamax; Invitrogen). Cultures 
were kept in a standard cell incubator (37°C, 5% CO2, 95% 
humidity), and the culture medium was exchanged three 
times weekly. For conditional microglia depletion, GCV (5 
µg ml−1) was added from 0–21 dpi reading GCV at each 
medium change. PLCs were obtained from 3–4-mo-old 
mice by peritoneal lavage using ice-cold PBS. 700,000 PLCs 
(counting cells with a large cell body) were added to each 
insert containing 10 freshly plated preinfected brain slices 
(70,000 PLCs/COCS). Alternatively, PLCs were sorted by 
MACS according to the manufacturer's (Miltenyi Biotec) 
protocol using antibodies raised against CD11b and CD19. 
Macrophages (CD19−, CD11b+) were added at 700,000 
cells/insert. The purity of the sorted cell populations and the 
total PLCs were analyzed by flow cytometry analysis accord-
ing to standard protocols using antibodies against CD3, 
CD19, and CD11b. Slices were harvested and analyzed for 
mRNA, protein or fixed for immunohistochemistry at 
various time points.
Intracerebral prion inoculation. Mice were intracerebrally in-
oculated with 30 µl of brain homogenate diluted in PBS with 
5% BSA and containing 3 × 5 log LD50 U of RML6. Scrapie 
was diagnosed according to clinical criteria (ataxia, kyphosis, 
priapism, and hind leg paresis). Mice were sacrificed on the 
day of onset of terminal clinical signs of scrapie.
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Osmotic pump implantation. Tga20+/+;TK+ and tga20+/+;TK− 
mice were intracerebrally inoculated with RML6 (3 × 5 log 
LD50 U, 30 µl). At 38 dpi, mice were anesthetized using iso-
fluorane and an intraventricular catheter was implanted in the 
right lateral ventricle. The primed pump loaded with GCV 
(50 mg ml−1) or PBS was placed subcutaneously and con-
nected to the catheter. Mice received pre- and postoperative 
care by injection of opioids (Temgesic; 2 µg g−1 bodyweight), 
NSA IDs (Finadyne; 5 µg g−1 bodyweight), and glucoisotonic 
solution and were treated with antibiotics (Borgal; 0.1% in 
drinking water). Mice were kept for 2 d on a 37°C heating 
pad to improve surgical recovery. At terminal disease, mice 
were sacrificed by CO2 inhalation, and brain, spinal cord, and 
cardiac blood were immediately collected. To monitor possi-
ble hematological changes, blood was analyzed by manually 
counting total RBCs and WBCs after lysis of RBCs. Hema-
tocrit (the ratio of the packed blood volume over the total 
volume) was determined by spinning blood in heparin tubes, 
and then the hemoglobin concentration was determined 
using Drabkin's reagent (Drabkin and Austin, 1935).
Quantitative real-time PCR (qRT-PCR). Total RNA from 
brain or cultured slices was extracted using TRIzol (Invitro-
gen) according to the manufacturer’s instruction. The quality 
of RNA was analyzed by Bioanalyzer 2100 (Agilent Technol-
ogies), RNAs with RNA integrity number >6 were used for 
cDNA synthesis. cDNA were synthesized from ∼1 µg total 
RNA using QuantiTect Reverse Transcription kit (QIA GEN) 
according to the manufacturer’s instruction. qRT-PCR was 
performed using the SYBR Green PCR Master Mix (Roche) 
on a ViiA7 Real-Time PCR system (Applied Biosystems).
The following primer pairs were used: GAP DH sense 
5′-CCA CCC CAG CAA GGA GACT-3′; antisense, 5′-GAA 
ATT GTG AGG GAG ATG CT-3′. TNF sense, 5′-CAT CTT 
CTC AAA ATT CGA GTG ACAA-3′; antisense, 5′-TGG 
GAG TAG ACA AGG TAC AAC CC-3′. IL-1β sense, 5′-CAA 
CCA ACA AGT GAT ATT CTC CATG-3′; antisense, 5′-GAT 
CCA CAC TCT CCA GCT GCA-3′. RAN TES sense, 5′-
ATG CCG ATT TTC CCA GGA CC-3′; antisense, 5′-TTT 
GCC TAC CTC TCC CTA CTG-3′. MCP-1 sense, 5′-TTA 
AAA AAC CTG GAT CGG AAC CAA-3′; antisense, 5′-GCA 
TTA GCT TCA GAT TTA CGG GT-3′. IL-6 sense, 5′-TCC 
AAT GCT CTC CTA ACA GAT AAG-3′; antisense, 5′-CAA 
GAT GAA TTG GAT GGT CTTG-3′. Expression levels were 
normalized using GAP DH.
Western blot analysis. To detect PrPSc in COCS, cultures 
were washed twice in PBS and the tissue was scraped off the 
membrane using 10–15 µl PBS per slice and homogenized by 
trituration using a 30-G syringe, followed by 2 × 30-s pulses 
in an ultrasound bath. Protein concentration was determined 
using the bicinchoninic acid assay (Thermo Fisher Scientific). 
Samples containing the same amount of total protein were 
digested with PK (20 µg protein in 20 µl, digested with 25 µg 
ml−1 PK) in digestion buffer (0.5% wt/vol sodium deoxycho-
late and 0.5% vol/vol Nonidet P-40 in PBS) for 30 min at 
37°C. PK digestion was stopped by adding loading buffer 
(NuPAGE; Invitrogen) and boiling the samples at 95°C for 5 
min. Proteins were separated on a 12% Bis-Tris polyacryl-
amide gel (NuPAGE; Invitrogen) and blotted onto a nitrocel-
lulose membrane. Membranes were blocked with 5% wt/vol 
Topblock (LuBioScience) in Tris-buffered saline supple-
mented with Tween (150 mM NaCl, 10 mM Tris HCl, and 
0.05% vol/vol Tween 20) and incubated with POM1 mouse 
IgG1 antibody to PrPC (anti-PrPC; 200 ng ml–1) in 1% Top-
block. Secondary antibodies used was horseradish peroxidase 
(HRP)–conjugated rabbit anti–mouse IgG1 (1:10,000; 
Zymed) and the blots were developed using SuperSignal West 
Pico chemiluminescent substrate (Thermo Fisher Scientific) 
using the LAS-3000 system (FujiFilm). To detect PrPC in the 
IL34−/− and IL34+/+ (WT) brains, one hemisphere from each 
brain was homogenized with buffer PBS containing 0.5% 
Nonidet P-40 and 0.5% CHA PSO. Total protein concentra-
tion was determined using the bicinchoninic acid assay 
(Thermo Fisher Scientific). Approximately 8 µg proteins were 
loaded and separated on a 12% Bis-Tris polyacrylamide gel 
(NuPAGE; Invitrogen) and then blotted onto a nitrocellulose 
membrane. Membranes were blocked with 5% wt/vol Top-
block (LuBioScience) in PBS supplemented with 0.05% 
Tween 20 (vol/vol) and incubated with primary antibodies 
POM1 in 1% Topblock (200 ng ml−1) overnight. After wash-
ing, the membranes were incubated with secondary antibody 
HRP-conjugated rabbit anti–mouse IgG1 (1:10,000; Zymed). 
Blots were developed using Luminata Crescendo Western 
HRP substrate (EMD Millipore) and visualized using the 
Stella system (model 3200; Raytest). To avoid variation in 
loading, the same blots were stripped and incubated with an 
anti-actin antibody (1:10,000; EMD Millipore). The PrPC sig-
nals were normalized to actin as a loading control. To detect 
PrPSc in prion infected IL34−/− and IL34+/+ (WT) brains, pri-
on-infected forebrains were homogenized in sterile 0.32 M 
sucrose in PBS. Total protein concentration was determined 
using the bicinchoninic acid assay (Thermo Fisher Scientific). 
Samples were adjusted to 20 µg protein in 20 µl and digested 
with 25 µg ml−1 PK in digestion buffer (PBS containing 0.5% 
[wt/vol] sodium deoxycholate and 0.5% [vol/vol] Nonidet 
P-40) for 30 min at 37°C. PK digestion was stopped by add-
ing loading buffer (Invitrogen) and boiling samples at 95°C 
for 5 min. Proteins were then separated on a 12% Bis-Tris 
polyacrylamide gel (NuPAGE; Invitrogen) and blotted onto a 
nitrocellulose membrane. POM1 and HRP-conjugated rab-
bit anti–mouse IgG1 were used as primary and secondary 
antibodies, respectively. Blots were developed using Luminata 
Crescendo Western HRP substrate (Millipore) and visualized 
using the LAS-3000 system (FujiFilm). To detect Iba-1 and 
GFAP in prion-infected brains by Western blot, 20 µg of total 
brain protein were loaded and anti–Iba-1 antibody (1:1,000; 
Wako) and anti-GFAP antibody (D1F4Q) XP Rabbit mAb 
(1:3,000; Cell Signaling Technology) were used. Actin was 
used as loading control.
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Immunohistochemistry. For immunohistochemistry of 
COCS, the organotypic slices were fixed in 4% wt/vol PFA 
overnight at 4°C. Membrane inserts were washed and incu-
bated for 1  h in blocking buffer (0.05% [vol/vol] Triton 
X-100 and 3% vol/vol goat serum dissolved in PBS), and 
then incubated for 3 d at 4°C with primary antibodies diluted 
in blocking buffer. Slices were stained with mouse anti-Neu-
ronal Nuclei (NeuN, 1 µg ml−1; Serotec) primary antibodies 
and Alexa Fluor 488–conjugated secondary antibody (3 µg 
ml–1; Molecular Probes), and then counterstained with DAPI 
(1 µg ml–1). For quantification of NeuN immunoreactivity, 
images were recorded using a 4× lens on an Olympus BX61 
fluorescence microscope equipped with a cooled black and 
white CCD camera. For quantification purposes all pictures 
were acquired at identical exposure times and the area of im-
munoreactivity was determined with image analysis software 
analySIS version 5.0, using identical grayscale threshold set-
tings for identifying positive pixels. For quantification of mi-
croglia density, a 63× oil lens was used to record micrographs 
on a Leica SP5 confocal laser-scanning microscope.
For immunohistochemistry of prion-infected brains, 
formalin-fixed tissues were treated with concentrated formic 
acid for 60 min to inactivate prion infectivity, and then em-
bedded in paraffin. Paraffin sections (2 µm) of brains were 
stained with hematoxylin and eosin (H&E). After deparaf-
finization through graded alcohols, antibodies GFAP (1:300; 
DAKO) for astrocytes were applied and visualized using stan-
dard methods, Iba-1 (1:1,000; Wako) was used for highlight-
ing activated microglial cells. Stainings were visualized using 
an IVI EW DAB Detection kit (Ventana), with a hematoxylin 
counterstain applied subsequently. For the histological detec-
tion of partially PK-resistant prion protein deposition, depar-
affinized sections were pretreated with formaldehyde for 30 
min and with 98% formic acid for 6 min, and then washed in 
distilled water for 30 min. Sections were incubated in Ventana 
buffer and stains were performed on a NEX EX immunohis-
tochemistry robot (Ventana) using an IVI EW DAB Detection 
kit (Ventana). After incubation with protease 1 (Ventana) for 
16 min, sections were incubated with anti-PrP SAF-84 (SPI 
bio; A03208; 1:200) for 32 min. Sections were counterstained 
with hematoxylin. Sections were imaged using a Zeiss Ax-
iophot light microscope. Quantification of Iba-1 and GFAP 
staining was performed on acquired images, where regions 
of interest were drawn, and the percentage of brown Iba-1 
and GFAP staining over the total area was quantified using 
in-house–developed software. The operator was blind to the 
genotype and treatment of the analyzed tissues.
Scoring of microglia depletion. To score microglia depletion 
in prion-infected CD11b-HSV TK mice, hemibrains were 
fixed in formalin and thin sagittal brain sections were stained 
for Iba1 (Wako). Brain sections were scanned at 40× magnifi-
cation using a Hamamatsu tissue scanner (Nanozoomer), then 
microglia were counted automatically using the Cavalieri es-
timator method with a counting grid size of 34.5 × 34.5 
µm as described elsewhere (Long et al., 1998). Staining arti-
facts were manually excluded and ambiguous features were 
counted both as a positive and a negative event. Representative 
areas in the superior frontal cortex and central cerebellar folia 
were counted in two 50-µm step sections for each mouse and 
normalized to the result for the tga20+/+;TK+ RML6 group.
Statistical analysis. Results are presented as the mean of rep-
licas ± SEM. We used one-way ANO VA with Tukey’s post-
test for multicolumn comparison for comparison of all 
columns to a control column for statistical analysis of experi-
ments involving the comparison of three or more samples. 
Unpaired Student’s t test was used for comparing two sam-
ples. For in vivo experiments, all groups were compared by 
Log-rank (Mantel-Cox) test. P-values <0.05 were considered 
statistically significant.
Online supplemental material. Fig. S1 describes hematological 
analyses of peripheral blood in PBS or GCV-treated tga20/
CD11b-HSV TK mice inoculated with RML or NBH. 
Online supplemental material is available at http ://www .jem 
.org /cgi /content /full /jem .20151000 /DC1.
ACKNOWLEDgMENTS
We thank the team of the Institute of Neuropathology, University Hospital Zurich, 
and in particular M. Delic, K. Arroyo, and M. König, for technical assistance, and M. 
Bieri for help with imaging and software development. We also thank Marco Colonna 
from Washington University School of Medicine (St. Louis, MO) for providing us with 
IL34−/− mice. 
A. Aguzzi is the recipient of an Advanced Grant of the European Research Coun-
cil (ERC, No. 250356) and is supported by grants from the European Union (NEU RIN 
OX), the Swiss National Foundation (including a Sinergia grant), the Swiss Initiative 
in Systems Biology, SystemsX.ch (PrionX, SynucleiX), the Novartis Research Founda-
tion, the Gelu Foundation, and the Klinische Forschungsschwerpunkte (“small RNAs” 
and “Human Hemato-Lymphatic Diseases”). C. Zhu is the recipient of a Young Scien-
tist Stipend of the Ernst-Jung Foundation. K. Frauenknecht is supported by a Career 
Development Award of the Stavros Niarchos Foundation. The funders had no role in 
study design, data collection and analysis, decision to publish, or preparation 
of the manuscript. 
The authors declare no competing financial interests.
Submitted: 16 June 2015
Accepted: 5 April 2016
REfERENCES
Aguzzi, A., and J. Falsig. 2012. Prion propagation, toxicity and degradation. 
Nat. Neurosci. 15:936–939. http ://dx .doi .org /10 .1038 /nn .3120
Aguzzi, A., B.A. Barres, and M.L. Bennett. 2013a. Microglia: scapegoat, 
saboteur, or something else? Science. 339:156–161. http ://dx .doi .org /10 
.1126 /science .1227901
Aguzzi, A., M. Nuvolone, and C. Zhu. 2013b. The immunobiology of prion 
diseases. Nat. Rev. Immunol. 13:888–902. http ://dx .doi .org /10 .1038 /
nri3553
Aguzzi, A., J. Kranich, and N.J. Krautler. 2014. Follicular dendritic cells: 
origin, phenotype, and function in health and disease. Trends Immunol. 
35:105–113. http ://dx .doi .org /10 .1016 /j .it .2013 .11 .001
Alliot, F., I. Godin, and B. Pessac. 1999. Microglia derive from progenitors, 
originating from the yolk sac, and which proliferate in the brain. Brain 
 o
n
 June 1, 2016
jem.rupress.org
D
ow
nloaded from
 
Published May 16, 2016
Microglia confer neuroprotection in prion diseases | Zhu et al.1058
Res. Dev. Brain Res. 117:145–152. http ://dx .doi .org /10 .1016 /S0165 
-3806(99)00113 -3
Baker, C.A., D. Martin, and L. Manuelidis. 2002. Microglia from Creutzfeldt-
Jakob disease-infected brains are infectious and show specific mRNA 
activation profiles. J. Virol. 76:10905–10913. http ://dx .doi .org /10 .1128 /
JVI .76 .21 .10905 -10913 .2002
Brown, D.R., B. Schmidt, and H.A. Kretzschmar. 1996. Role of microglia and 
host prion protein in neurotoxicity of a prion protein fragment. Nature. 
380:345–347. http ://dx .doi .org /10 .1038 /380345a0
Chen, S.K., P. Tvrdik, E. Peden, S. Cho, S. Wu, G. Spangrude, and M.R. 
Capecchi. 2010. Hematopoietic origin of pathological grooming in 
Hoxb8 mutant mice. Cell. 141:775–785. http ://dx .doi .org /10 .1016 /j 
.cell .2010 .03 .055
Davalos, D., J. Grutzendler, G. Yang, J.V. Kim, Y. Zuo, S. Jung, D.R. Littman, 
M.L. Dustin, and W.B. Gan. 2005. ATP mediates rapid microglial 
response to local brain injury in vivo. Nat. Neurosci. 8:752–758. http ://
dx .doi .org /10 .1038 /nn1472
Derecki, N.C., J.C. Cronk, Z. Lu, E. Xu, S.B. Abbott, P.G. Guyenet, and J. 
Kipnis. 2012. Wild-type microglia arrest pathology in a mouse model 
of Rett syndrome. Nature. 484:105–109. http ://dx .doi .org /10 .1038 /
nature10907
Drabkin, D.L., and J.H. Austin. 1935. Preparations from washed blood cells; 
nitric oxide hemoglobin and sulfhemoglobin. J. Biol. Chem. 112:51–65.
Falsig, J., and A. Aguzzi. 2008. The prion organotypic slice culture assay--POS 
CA. Nat. Protoc. 3:555–562. http ://dx .doi .org /10 .1038 /nprot .2008 .13
Falsig, J., C. Julius, I. Margalith, P. Schwarz, F.L. Heppner, and A. Aguzzi. 
2008. A versatile prion replication assay in organotypic brain slices. Nat. 
Neurosci. 11:109–117. http ://dx .doi .org /10 .1038 /nn2028
Falsig, J., T. Sonati, U.S. Herrmann, D. Saban, B. Li, K. Arroyo, B. Ballmer, P.P. 
Liberski, and A. Aguzzi. 2012. Prion pathogenesis is faithfully reproduced 
in cerebellar organotypic slice cultures. PLoS Pathog. 8:e1002985. http ://
dx .doi .org /10 .1371 /journal .ppat .1002985
Fischer, M., T. Rülicke, A. Raeber, A. Sailer, M. Moser, B. Oesch, S. Brandner, 
A. Aguzzi, and C. Weissmann. 1996. Prion protein (PrP) with amino- 
proximal deletions restoring susceptibility of PrP knockout mice to scra-
pie. EMBO J. 15:1255–1264.
Giese, A., D.R. Brown, M.H. Groschup, C. Feldmann, I. Haist, and H.A. 
Kretzschmar. 1998. Role of microglia in neuronal cell death in prion 
disease. Brain Pathol. 8:449–457. http ://dx .doi .org /10 .1111 /j .1750 
-3639 .1998 .tb00167 .x
Ginhoux, F., M. Greter, M. Leboeuf, S. Nandi, P. See, S. Gokhan, M.F. Mehler, 
S.J. Conway, L.G. Ng, E.R. Stanley, et al. 2010. Fate mapping analysis 
reveals that adult microglia derive from primitive macrophages. Science. 
330:841–845. http ://dx .doi .org /10 .1126 /science .1194637
Gómez-Nicola, D., N.L. Fransen, S. Suzzi, and V.H. Perry. 2013. Regulation 
of microglial proliferation during chronic neurodegeneration. J. 
Neurosci. 33:2481–2493. http ://dx .doi .org /10 .1523 /JNE URO SCI 
.4440 -12 .2013
Gómez-Nicola, D., S.T. Schetters, and V.H. Perry. 2014. Differential role 
of CCR2 in the dynamics of microglia and perivascular macrophages 
during prion disease. Glia. 62:1041–1052. http ://dx .doi .org /10 .1002 /
glia .22660
Grathwohl, S.A., R.E. Kälin, T. Bolmont, S. Prokop, G. Winkelmann, S.A. 
Kaeser, J. Odenthal, R. Radde, T. Eldh, S. Gandy, et al. 2009. Formation 
and maintenance of Alzheimer’s disease β-amyloid plaques in the 
absence of microglia. Nat. Neurosci. 12:1361–1363. http ://dx .doi .org /10 
.1038 /nn .2432
Greter, M., I. Lelios, P. Pelczar, G. Hoeffel, J. Price, M. Leboeuf, T.M. Kündig, 
K. Frei, F. Ginhoux, M. Merad, and B. Becher. 2012. Stroma-derived 
interleukin-34 controls the development and maintenance of langerhans 
cells and the maintenance of microglia. Immunity. 37:1050–1060. http ://
dx .doi .org /10 .1016 /j .immuni .2012 .11 .001
Hanisch, U.K., and H. Kettenmann. 2007. Microglia: active sensor and 
versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 
10:1387–1394. http ://dx .doi .org /10 .1038 /nn1997
Heppner, F.L., M. Greter, D. Marino, J. Falsig, G. Raivich, N. Hövelmeyer, 
A. Waisman, T. Rülicke, M. Prinz, J. Priller, et al. 2005. Experimental 
autoimmune encephalomyelitis repressed by microglial paralysis. Nat. 
Med. 11:146–152. http ://dx .doi .org /10 .1038 /nm1177
Herrmann, U.S., T. Sonati, J. Falsig, R.R. Reimann, P. Dametto, T. O’Connor, 
B. Li, A. Lau, S. Hornemann, S. Sorce, et al. 2015. Prion infections and 
anti-PrP antibodies trigger converging neurotoxic pathways. PLoS 
Pathog. 11:e1004662. http ://dx .doi .org /10 .1371 /journal .ppat .1004662
Hughes, M.M., R.H. Field, V.H. Perry, C.L. Murray, and C. Cunningham. 
2010. Microglia in the degenerating brain are capable of phagocytosis of 
beads and of apoptotic cells, but do not efficiently remove PrPSc, even 
upon LPS stimulation. Glia. 58:2017–2030. http ://dx .doi .org /10 .1002 
/glia .21070
Jeffrey, M., C.M. Goodsir, M.E. Bruce, P.A. McBride, and C. Farquhar. 1994. 
Morphogenesis of amyloid plaques in 87V murine scrapie. Neuropathol. 
Appl. Neurobiol. 20:535–542. http ://dx .doi .org /10 .1111 /j .1365 -2990 
.1994 .tb01007 .x
Kierdorf, K., D. Erny, T. Goldmann, V. Sander, C. Schulz, E.G. Perdiguero, P. 
Wieghofer, A. Heinrich, P. Riemke, C. Hölscher, et al. 2013. Microglia 
emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent 
pathways. Nat. Neurosci. 16:273–280. http ://dx .doi .org /10 .1038 /nn 
.3318
Klein, T.R., D. Kirsch, R. Kaufmann, and D. Riesner. 1998. Prion rods 
contain small amounts of two host sphingolipids as revealed by thin-
layer chromatography and mass spectrometry. Biol. Chem. 379:655–666. 
http ://dx .doi .org /10 .1515 /bchm .1998 .379 .6 .655
Kranich, J., N.J. Krautler, J. Falsig, B. Ballmer, S. Li, G. Hutter, P. Schwarz, R. 
Moos, C. Julius, G. Miele, and A. Aguzzi. 2010. Engulfment of cerebral 
apoptotic bodies controls the course of prion disease in a mouse strain-
dependent manner. J. Exp. Med. 207:2271–2281. http ://dx .doi .org /10 
.1084 /jem .20092401
Long, J.M., A.N. Kalehua, N.J. Muth, J.M. Hengemihle, M. Jucker, 
M.E. Calhoun, D.K. Ingram, and P.R. Mouton. 1998. Stereological 
estimation of total microglia number in mouse hippocampus. J. 
Neurosci. Methods. 84:101–108. http ://dx .doi .org /10 .1016 /S0165 
-0270(98)00100 -99821640
McHugh, D., T. O’Connor, J. Bremer, and A. Aguzzi. 2012. ZyFISH: a simple, 
rapid and reliable zygosity assay for transgenic mice. PLoS One. 7:e37881. 
http ://dx .doi .org /10 .1371 /journal .pone .0037881
Mildner, A., B. Schlevogt, K. Kierdorf, C. Böttcher, D. Erny, M.P. Kummer, M. 
Quinn, W. Brück, I. Bechmann, M.T. Heneka, et al. 2011. Distinct and 
non-redundant roles of microglia and myeloid subsets in mouse models 
of Alzheimer’s disease. J. Neurosci. 31:11159–11171. http ://dx .doi .org 
/10 .1523 /JNE URO SCI .6209 -10 .2011
Nimmerjahn, A., F. Kirchhoff, and F. Helmchen. 2005. Resting microglial 
cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 
308:1314–1318. http ://dx .doi .org /10 .1126 /science .1110647
Paolicelli, R.C., G. Bolasco, F. Pagani, L. Maggi, M. Scianni, P. Panzanelli, 
M. Giustetto, T.A. Ferreira, E. Guiducci, L. Dumas, et al. 2011. Synaptic 
pruning by microglia is necessary for normal brain development. Science. 
333:1456–1458. http ://dx .doi .org /10 .1126 /science .1202529
Parkhurst, C.N., G. Yang, I. Ninan, J.N. Savas, J.R. Yates III, J.J. Lafaille, B.L. 
Hempstead, D.R. Littman, and W.B. Gan. 2013. Microglia promote 
learning-dependent synapse formation through brain-derived 
neurotrophic factor. Cell. 155:1596–1609. http ://dx .doi .org /10 .1016 /j 
.cell .2013 .11 .030
Rogers, J.T., J.M. Morganti, A.D. Bachstetter, C.E. Hudson, M.M. Peters, B.A. 
Grimmig, E.J. Weeber, P.C. Bickford, and C. Gemma. 2011. CX3CR1 
deficiency leads to impairment of hippocampal cognitive function and 
 o
n
 June 1, 2016
jem.rupress.org
D
ow
nloaded from
 
Published May 16, 2016
1059JEM Vol. 213, No. 6
synaptic plasticity. J. Neurosci. 31:16241–16250. http ://dx .doi .org /10 
.1523 /JNE URO SCI .3667 -11 .2011
Rouvinski, A., S. Karniely, M. Kounin, S. Moussa, M.D. Goldberg, G. Warburg, 
R. Lyakhovetsky, D. Papy-Garcia, J. Kutzsche, C. Korth, et al. 2014. Live 
imaging of prions reveals nascent PrPSc in cell-surface, raft-associated 
amyloid strings and webs. J. Cell Biol. 204:423–441. http ://dx .doi .org 
/10 .1083 /jcb .201308028
Schafer, D.P., E.K. Lehrman, A.G. Kautzman, R. Koyama, A.R. Mardinly, 
R. Yamasaki, R.M. Ransohoff, M.E. Greenberg, B.A. Barres, and B. 
Stevens. 2012. Microglia sculpt postnatal neural circuits in an activity 
and complement-dependent manner. Neuron. 74:691–705. http ://dx 
.doi .org /10 .1016 /j .neuron .2012 .03 .026
Schulz, C., E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, 
K. Kierdorf, M. Prinz, B. Wu, S.E. Jacobsen, J.W. Pollard, et al. 2012. A 
lineage of myeloid cells independent of Myb and hematopoietic stem 
cells. Science. 336:86–90. http ://dx .doi .org /10 .1126 /science .1219179
Sonati, T., R.R. Reimann, J. Falsig, P.K. Baral, T. O’Connor, S. Hornemann, S. 
Yaganoglu, B. Li, U.S. Herrmann, B. Wieland, et al. 2013. The toxicity of 
antiprion antibodies is mediated by the flexible tail of the prion protein. 
Nature. 501:102–106. http ://dx .doi .org /10 .1038 /nature12402
Wang, Y., K.J. Szretter, W. Vermi, S. Gilfillan, C. Rossini, M. Cella, A.D. Barrow, 
M.S. Diamond, and M. Colonna. 2012. IL-34 is a tissue-restricted ligand 
of CSF1R required for the development of Langerhans cells and microglia. 
Nat. Immunol. 13:753–760. http ://dx .doi .org /10 .1038 /ni .2360
Williams, A., P.J. Lucassen, D. Ritchie, and M. Bruce. 1997. PrP deposition, 
microglial activation, and neuronal apoptosis in murine scrapie. Exp. 
Neurol. 144:433–438. http ://dx .doi .org /10 .1006 /exnr .1997 .6424
Zhan, Y., R.C. Paolicelli, F. Sforazzini, L. Weinhard, G. Bolasco, F. Pagani, 
A.L. Vyssotski, A. Bifone, A. Gozzi, D. Ragozzino, and C.T. Gross. 2014. 
Deficient neuron-microglia signaling results in impaired functional brain 
connectivity and social behavior. Nat. Neurosci. 17:400–406. http ://dx 
.doi .org /10 .1038 /nn .3641
 o
n
 June 1, 2016
jem.rupress.org
D
ow
nloaded from
 
Published May 16, 2016
